RYTM · Forms 3, 4, 5
Insider trades at RHYTHM PHARMACEUTICALS, INC.
6 insiders sold $28.8M of RHYTHM PHARMACEUTICALS, INC. stock on the open market in the last 90 days.
Every Form 3, 4 and 5 filed for RHYTHM PHARMACEUTICALS, INC. (RYTM) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| David P Meeker | President and CEO | Option exercise | 50,000 | $6.05 | $303K | Form 4 | |
| David P Meeker | President and CEO | Sell (10b5-1 plan) | 6,439 | $101.75 | $655K | Form 4 | |
| David P Meeker | President and CEO | Sell (10b5-1 plan) | 30,746 | $102.35 | $3.1M | Form 4 | |
| David P Meeker | President and CEO | Sell (10b5-1 plan) | 8,698 | $103.43 | $900K | Form 4 | |
| David P Meeker | President and CEO | Sell (10b5-1 plan) | 1,817 | $104.55 | $190K | Form 4 | |
| David P Meeker | President and CEO | Sell (10b5-1 plan) | 2,300 | $105.19 | $242K | Form 4 | |
| Hunter C Smith | Chief Financial Officer | Option exercise | 57,187 | $25.79 | $1.5M | Form 4 | |
| Hunter C Smith | Chief Financial Officer | Sell (10b5-1 plan) | 23,072 | $104.59 | $2.4M | Form 4 | |
| Hunter C Smith | Chief Financial Officer | Sell (10b5-1 plan) | 11,514 | $105.37 | $1.2M | Form 4 | |
| Hunter C Smith | Chief Financial Officer | Sell (10b5-1 plan) | 28,188 | $106.20 | $3M | Form 4 | |
| Manher Joshi | Chief Medical Officer | Options or other derivatives | Form 4 | ||||
| Manher Joshi | Chief Medical Officer | Became an insider (Form 3) | Form 3 | ||||
| Joseph Shulman | Chief Technical Officer | Option exercise | 2,024 | $6.80 | $14K | Form 4 | |
| Joseph Shulman | Chief Technical Officer | Sell (10b5-1 plan) | 5,079 | $119.75 | $608K | Form 4 | |
| Alastair Garfield | Chief Scientific Officer | Sell (10b5-1 plan) | 2,007 | $116.11 | $233K | Form 4 | |
| Alastair Garfield | Chief Scientific Officer | Sell (10b5-1 plan) | 1,556 | $117.08 | $182K | Form 4 | |
| Alastair Garfield | Chief Scientific Officer | Sell (10b5-1 plan) | 3,400 | $118.28 | $402K | Form 4 | |
| Alastair Garfield | Chief Scientific Officer | Sell (10b5-1 plan) | 800 | $119.17 | $95K | Form 4 | |
| Jennifer Kayden Lee | EVP, Head of North America | Option exercise | 35,000 | $24.29 | $850K | Form 4 | |
| Jennifer Kayden Lee | EVP, Head of North America | Option exercise | 21,601 | $6.80 | $147K | Form 4 | |
| Jennifer Kayden Lee | EVP, Head of North America | Sell (10b5-1 plan) | 75,834 | $117.38 | $8.9M | Form 4 | |
| Yann Mazabraud | EVP, Head of International | Option exercise | 46,625 | $6.80 | $317K | Form 4 | |
| Yann Mazabraud | EVP, Head of International | Sell (10b5-1 plan) | 2,300 | $111.80 | $257K | Form 4 | |
| Yann Mazabraud | EVP, Head of International | Sell (10b5-1 plan) | 1,000 | $112.86 | $113K | Form 4 | |
| Yann Mazabraud | EVP, Head of International | Sell (10b5-1 plan) | 3,605 | $114.70 | $413K | Form 4 | |
| Yann Mazabraud | EVP, Head of International | Sell (10b5-1 plan) | 14,568 | $115.43 | $1.7M | Form 4 | |
| Yann Mazabraud | EVP, Head of International | Sell (10b5-1 plan) | 18,208 | $116.49 | $2.1M | Form 4 | |
| Yann Mazabraud | EVP, Head of International | Sell (10b5-1 plan) | 17,319 | $117.47 | $2M | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.